SG11201908787WA - Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap - Google Patents
Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fapInfo
- Publication number
- SG11201908787WA SG11201908787WA SG11201908787WA SG11201908787WA SG 11201908787W A SG11201908787W A SG 11201908787WA SG 11201908787W A SG11201908787W A SG 11201908787WA SG 11201908787W A SG11201908787W A SG 11201908787WA
- Authority
- SG
- Singapore
- Prior art keywords
- schlieren
- international
- roche
- wagistrasse
- antigen binding
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 6
- 102000036639 antigens Human genes 0.000 title abstract 6
- 108091007433 antigens Proteins 0.000 title abstract 6
- 230000027455 binding Effects 0.000 title abstract 5
- 230000009870 specific binding Effects 0.000 title abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 101150013553 CD40 gene Proteins 0.000 abstract 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 244000061408 Eugenia caryophyllata Species 0.000 abstract 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000002950 fibroblast Anatomy 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 October 2018 (11.10.2018) WIPO I PCT 0111111010 0111 °nolo OH H ioo IIIII IH oimIE (10) International Publication Number WO 2018/185045 Al (51) International Patent Classification: C07K 16/28 (2006.01) A61K 39/00 (2006.01) C07K 16/40 (2006.01) (21) International Application Number: PCT/EP2018/058384 (22) International Filing Date: 03 April 2018 (03.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17164725.8 04 April 2017 (04.04.2017) EP 18158751.0 27 February 2018 (27.02.2018) EP (71) Applicant (for all designated States except US): F. HOFF- MANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH). (71) Applicant (for US only): HOFFMANN-LA ROCHE INC. [US/US]; Overlook at Great Notch, 150 Clove Road, 8th Floor, Suite 8 - Legal Department, Little Falls, New Jer- sey 07424 (US). (72) Inventors: BRUENKER, Peter; c/o Roche Glycart AG, Wagistrasse 18, 8952 Schlieren (CH). BUJOTZEK, Alexander; Fuerstenrieder Str. 82c, 80686 Muenchen (DE). DUERR, Harald; Gustav-Meyrink-Str. 7a, 82319 Starnberg (DE). GEORGES, Guy; Am Berggraben 11, 82392 Habach (DE). KLEIN, Christian; c/o Roche Glycart AG, Wagistrasse 18, 8952 Schlieren (CH). LECLAIR, Stephane; Schulstr. 12 1 / 4 , 82131 Gauting (DE). RAPP, Moritz; c/o Roche Glycart AG, Wagis- trasse 18, 8952 Schlieren (CH). SUM, Eva Carina; c/o Roche Glycart AG, Wagistrasse 18, 8952 Schlieren (CH). TRUMPFHELLER, Christine; c/o Roche Glycart AG, Wagistrasse 18, 8952 Schlieren (CH). UMASTA, Pablo; c/ o Roche Glycart AG, Wagistrasse 18, 8952 Schlieren (CH). (74) Agent: KLOSTERMEYER RAUBER, Doerte; Gren- zacherstrasse 124, 4070 Basel (CH). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) (54) Title: NOVEL BISPECIFIC ANTIGEN BINDING MOLECULES CAPABLE OF SPECIFIC BINDING TO CD40 AND TO FAP (57) : The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to CD40, and(b) at least one antigen binding domain capable of specific binding to a target cell antigen,in particular Fibroblast Activation Protein (FAP),and to methods of producing these molecules and to methods of using the same.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17164725 | 2017-04-04 | ||
EP18158751 | 2018-02-27 | ||
PCT/EP2018/058384 WO2018185045A1 (en) | 2017-04-04 | 2018-04-03 | Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201908787WA true SG11201908787WA (en) | 2019-10-30 |
Family
ID=61913152
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201908787W SG11201908787WA (en) | 2017-04-04 | 2018-04-03 | Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap |
Country Status (20)
Country | Link |
---|---|
US (2) | US20180340030A1 (en) |
EP (1) | EP3606956A1 (en) |
JP (2) | JP6997209B2 (en) |
KR (1) | KR102364599B1 (en) |
CN (1) | CN110402255B (en) |
AU (1) | AU2018247796A1 (en) |
BR (1) | BR112019017753A2 (en) |
CA (1) | CA3053358A1 (en) |
CL (1) | CL2019002542A1 (en) |
CO (1) | CO2019009432A2 (en) |
CR (1) | CR20190427A (en) |
IL (1) | IL269396A (en) |
MA (1) | MA49039A (en) |
MX (1) | MX2019011907A (en) |
PE (1) | PE20200006A1 (en) |
PH (1) | PH12019502294A1 (en) |
RU (1) | RU2766234C2 (en) |
SG (1) | SG11201908787WA (en) |
TW (1) | TWI704158B (en) |
WO (1) | WO2018185045A1 (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3559034B1 (en) | 2016-12-20 | 2020-12-02 | H. Hoffnabb-La Roche Ag | Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists |
BR112019013189A2 (en) | 2017-01-03 | 2019-12-10 | Hoffmann La Roche | bispecific antigen binding molecules, polynucleotide, host cell, bispecific antigen binding molecule production method, pharmaceutical composition, use, methods for inhibiting tumor cell growth in an individual and for treating cancer or an infectious disease |
CN110573528B (en) | 2017-03-29 | 2023-06-09 | 豪夫迈·罗氏有限公司 | Bispecific antigen binding molecules to costimulatory TNF receptors |
EP3619235A1 (en) | 2017-04-11 | 2020-03-11 | Inhibrx, Inc. | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same |
EP3703821A2 (en) * | 2017-11-01 | 2020-09-09 | F. Hoffmann-La Roche AG | Bispecific 2+1 contorsbodies |
CN111819198A (en) | 2017-12-28 | 2020-10-23 | 尤利乌斯·马克西米利安维尔茨堡大学 | Tumor Necrosis Factor (TNF) receptor superfamily (TNFRSF) receptor-activating antibody fusion proteins with non-Fc γ R dependent agonistic activity (TNFRSF receptor-activating antibody fusion proteins with non-Fc γ R dependent agonistic activity; TRAAFFIAA) |
US20200048350A1 (en) * | 2018-07-24 | 2020-02-13 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
JP7221379B2 (en) | 2018-10-01 | 2023-02-13 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Bispecific antigen-binding molecule comprising anti-FAP clone 212 |
MY198034A (en) | 2018-12-21 | 2023-07-27 | Hoffmann La Roche | Tumor-targeted agonistic cd28 antigen binding molecules |
JPWO2020230899A1 (en) | 2019-05-15 | 2020-11-19 | ||
JPWO2020230901A1 (en) * | 2019-05-15 | 2020-11-19 | ||
UY38995A (en) | 2019-12-20 | 2021-06-30 | Amgen Inc | MESOTHELIN TARGETING CD40 AGONIST MULTI-SPECIFIC ANTIBODY CONSTRUCTS FOR THE TREATMENT OF SOLID TUMORS |
AR121706A1 (en) | 2020-04-01 | 2022-06-29 | Hoffmann La Roche | OX40 AND FAP-TARGETED BSPECIFIC ANTIGEN-BINDING MOLECULES |
WO2021229067A1 (en) * | 2020-05-14 | 2021-11-18 | Molecular Partners Ag | Multispecific proteins |
EP4244254A1 (en) | 2020-11-16 | 2023-09-20 | F. Hoffmann-La Roche AG | Combination therapy with fap-targeted cd40 agonists |
BR112023018117A2 (en) | 2021-03-09 | 2023-10-31 | Hoffmann La Roche | IMMUNOCONJUGATES |
WO2022243261A1 (en) * | 2021-05-19 | 2022-11-24 | F. Hoffmann-La Roche Ag | Agonistic cd40 antigen binding molecules targeting cea |
CN117616049A (en) * | 2021-08-24 | 2024-02-27 | 江苏恒瑞医药股份有限公司 | FAP/CD40 binding molecule and medical application thereof |
WO2023046037A1 (en) * | 2021-09-24 | 2023-03-30 | 正大天晴药业集团股份有限公司 | Anti-cd40 antibody and use thereof |
CN116410326A (en) * | 2021-12-30 | 2023-07-11 | 三优生物医药(上海)有限公司 | anti-CD 40 xCLDN 18.2 bispecific antibody and uses thereof |
CN114480413B (en) * | 2022-01-14 | 2022-11-04 | 北京贝来生物科技有限公司 | Preparation method of genetically modified stem cells for activating tumor immune response |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
KR0184860B1 (en) | 1988-11-11 | 1999-04-01 | 메디칼 리써어치 카운실 | Single domain ligands receptors comprising said ligands methods for their production and use of said ligands |
DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
ES2206447T3 (en) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | HUMANIZED ANTIBODY FOR HEREGULINE. |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
JPH08511420A (en) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | Body |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
DE69830315T2 (en) | 1997-06-24 | 2006-02-02 | Genentech Inc., San Francisco | GALACTOSYLATED GLYCOPROTEIN CONTAINING COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
DE19742706B4 (en) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | lipocalin muteins |
ATE419009T1 (en) | 1997-10-31 | 2009-01-15 | Genentech Inc | METHODS AND COMPOSITIONS CONSISTING OF GLYCOPROTEIN GLYCOFORMS |
AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
AU782626B2 (en) | 1999-10-04 | 2005-08-18 | Medicago Inc. | Method for regulating transcription of foreign genes |
EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
NZ592087A (en) | 2001-08-03 | 2012-11-30 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
ES2326964T3 (en) | 2001-10-25 | 2009-10-22 | Genentech, Inc. | GLICOPROTEIN COMPOSITIONS. |
AR039067A1 (en) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | ANTIBODIES FOR CD40 |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
DE60332957D1 (en) | 2002-12-16 | 2010-07-22 | Genentech Inc | IMMUNOGLOBULIN VARIANTS AND ITS USES |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
AU2004253835B2 (en) | 2003-07-04 | 2009-01-29 | Affibody Ab | Polypeptides having binding affinity for HER2 |
AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
EA036531B1 (en) | 2003-11-05 | 2020-11-19 | Роше Гликарт Аг | Type ii anti-cd20 humanized antibody (variants), pharmaceutical composition comprising these antibody variants, and use thereof |
KR20060129246A (en) | 2003-12-05 | 2006-12-15 | 컴파운드 쎄라퓨틱스, 인크. | Inhibitors of type 2 vascular endothelial growth factor receptors |
EP1791565B1 (en) | 2004-09-23 | 2016-04-20 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
JO3000B1 (en) | 2004-10-20 | 2016-09-05 | Genentech Inc | Antibody Formulations. |
US8303955B2 (en) * | 2005-05-26 | 2012-11-06 | Seattle Genetics, Inc. | Humanized anti-CD40 antibodies and their methods of use |
EP1958957A1 (en) | 2007-02-16 | 2008-08-20 | NascaCell Technologies AG | Polypeptide comprising a knottin protein moiety |
JP5730576B2 (en) * | 2007-11-07 | 2015-06-10 | ジェネンテック, インコーポレイテッド | Methods and compositions for assessing B cell lymphoma responsiveness to treatment with anti-CD40 antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
PT2235064E (en) | 2008-01-07 | 2016-03-01 | Amgen Inc | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
US9676845B2 (en) * | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
WO2012002006A1 (en) | 2010-06-29 | 2012-01-05 | コニカミノルタエムジー株式会社 | Ultrasound diagnosis device and program |
SG187746A1 (en) * | 2010-08-13 | 2013-03-28 | Roche Glycart Ag | Anti-fap antibodies and methods of use |
PE20140303A1 (en) * | 2011-02-10 | 2014-03-22 | Roche Glycart Ag | MUTANT INTERLEUQUIN-2 POLYPEPTIDES |
PT2691417T (en) | 2011-03-29 | 2018-10-31 | Roche Glycart Ag | Antibody fc variants |
CN103748114B (en) * | 2011-08-23 | 2017-07-21 | 罗切格利卡特公司 | T cell activation bispecific antigen binding molecules |
ES2774160T3 (en) * | 2012-02-13 | 2020-07-17 | Seattle Childrens Hospital D/B/A Seattle Childrens Res Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
SG10201800535XA (en) * | 2012-08-07 | 2018-02-27 | Roche Glycart Ag | Composition comprising two antibodies engineered to have reduced and increased effector function |
US10131710B2 (en) * | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
UA118028C2 (en) * | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use |
JP6618463B2 (en) * | 2013-05-07 | 2019-12-11 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Trimeric antigen-binding molecule |
GB201311487D0 (en) * | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Bispecific molecules |
WO2015132598A1 (en) * | 2014-03-05 | 2015-09-11 | Ucl Business Plc | Chimeric antigen receptor (car) with antigen binding domains to the t cell receptor beta constant region |
RU2017108173A (en) * | 2014-08-14 | 2018-09-17 | Ф.Хоффманн-Ля Рош Аг | COMBINED THERAPY BASED ON ANTIBODIES ACTIVATING HUMAN CD40 AND ANTIBODIES TO HUMAN PD-L1 |
WO2016030350A1 (en) | 2014-08-29 | 2016-03-03 | F. Hoffmann-La Roche Ag | Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1 |
CN107074933B (en) | 2014-10-24 | 2021-03-19 | 豪夫迈·罗氏有限公司 | Antibody humanization based on VH-VL interdomain angles |
BR112017010324A2 (en) * | 2014-11-20 | 2018-05-15 | F. Hoffmann-La Roche Ag | method for treating or slowing cancer progression in an individual, molecules, methods for enhancing immune function in an individual and for selecting a patient for treatment, kits, pharmaceutical composition and uses of a combination of one molecule |
WO2017025698A1 (en) * | 2015-08-11 | 2017-02-16 | Queen Mary University Of London | Bispecific, cleavable antibodies |
JP7221379B2 (en) * | 2018-10-01 | 2023-02-13 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Bispecific antigen-binding molecule comprising anti-FAP clone 212 |
-
2018
- 2018-04-03 BR BR112019017753A patent/BR112019017753A2/en active Search and Examination
- 2018-04-03 MA MA049039A patent/MA49039A/en unknown
- 2018-04-03 JP JP2019554378A patent/JP6997209B2/en active Active
- 2018-04-03 TW TW107111767A patent/TWI704158B/en active
- 2018-04-03 RU RU2019134352A patent/RU2766234C2/en active
- 2018-04-03 PE PE2019001678A patent/PE20200006A1/en unknown
- 2018-04-03 US US15/943,821 patent/US20180340030A1/en not_active Abandoned
- 2018-04-03 MX MX2019011907A patent/MX2019011907A/en unknown
- 2018-04-03 EP EP18716574.1A patent/EP3606956A1/en active Pending
- 2018-04-03 SG SG11201908787W patent/SG11201908787WA/en unknown
- 2018-04-03 WO PCT/EP2018/058384 patent/WO2018185045A1/en unknown
- 2018-04-03 KR KR1020197032424A patent/KR102364599B1/en active IP Right Grant
- 2018-04-03 AU AU2018247796A patent/AU2018247796A1/en active Pending
- 2018-04-03 CR CR20190427A patent/CR20190427A/en unknown
- 2018-04-03 CN CN201880015543.7A patent/CN110402255B/en active Active
- 2018-04-03 CA CA3053358A patent/CA3053358A1/en active Pending
-
2019
- 2019-08-29 CO CONC2019/0009432A patent/CO2019009432A2/en unknown
- 2019-09-04 CL CL2019002542A patent/CL2019002542A1/en unknown
- 2019-09-16 IL IL26939619A patent/IL269396A/en unknown
- 2019-10-04 PH PH12019502294A patent/PH12019502294A1/en unknown
-
2021
- 2021-02-18 US US17/179,223 patent/US20210188992A1/en active Pending
- 2021-10-07 JP JP2021165225A patent/JP7288943B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2018185045A1 (en) | 2018-10-11 |
EP3606956A1 (en) | 2020-02-12 |
KR102364599B1 (en) | 2022-02-21 |
JP2022017275A (en) | 2022-01-25 |
TW201841939A (en) | 2018-12-01 |
JP7288943B2 (en) | 2023-06-08 |
RU2766234C2 (en) | 2022-02-10 |
PE20200006A1 (en) | 2020-01-06 |
CL2019002542A1 (en) | 2020-01-31 |
AU2018247796A1 (en) | 2019-08-29 |
CR20190427A (en) | 2019-11-01 |
JP6997209B2 (en) | 2022-02-04 |
BR112019017753A2 (en) | 2020-04-07 |
US20210188992A1 (en) | 2021-06-24 |
MA49039A (en) | 2020-02-12 |
TWI704158B (en) | 2020-09-11 |
CN110402255A (en) | 2019-11-01 |
CA3053358A1 (en) | 2018-10-11 |
MX2019011907A (en) | 2020-01-09 |
RU2019134352A3 (en) | 2021-07-21 |
PH12019502294A1 (en) | 2020-07-06 |
JP2020515276A (en) | 2020-05-28 |
IL269396A (en) | 2019-11-28 |
US20180340030A1 (en) | 2018-11-29 |
RU2019134352A (en) | 2021-05-05 |
KR20190137125A (en) | 2019-12-10 |
CN110402255B (en) | 2022-12-02 |
CO2019009432A2 (en) | 2019-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201908787WA (en) | Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap | |
SG11201909154SA (en) | Bispecific antibodies specifically binding to pd1 and lag3 | |
SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
SG11201908088RA (en) | Antibodies against pd-l1 | |
SG11201909012YA (en) | Key data processing method and apparatus, and server | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201909344SA (en) | Anti-lag3 antibodies | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
SG11201900677SA (en) | Combination therapies of chimeric antigen receptors adn pd-1 inhibitors | |
SG11201808196UA (en) | Neoantigens and methods of their use | |
SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
SG11201903825SA (en) | Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion | |
SG11201900885VA (en) | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule | |
SG11201810023QA (en) | Anti-tim-3 antibodies and methods of use thereof | |
SG11201804086VA (en) | Methods and compositions for nucleic acid analysis | |
SG11201804178YA (en) | Pd1 and/or lag3 binders | |
SG11201907162TA (en) | Methods for cell-type specific profiling to identify drug targets | |
SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
SG11201908784TA (en) | Improved antigen binding receptor formats | |
SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
SG11201903167QA (en) | Compounds and methods for reducing atxn3 expression | |
SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof |